477 related articles for article (PubMed ID: 16326745)
1. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
[TBL] [Abstract][Full Text] [Related]
2. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
[TBL] [Abstract][Full Text] [Related]
3. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
[TBL] [Abstract][Full Text] [Related]
4. The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane.
Chanard J; Lavaud S; Maheut H; Kazes I; Vitry F; Rieu P
Nephrol Dial Transplant; 2008 Jun; 23(6):2003-9. PubMed ID: 18156457
[TBL] [Abstract][Full Text] [Related]
5. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
Frank RD; Brandenburg VM; Lanzmich R; Floege J
Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
[TBL] [Abstract][Full Text] [Related]
6. [Minimal heparinization in dialysis patients with increased risk of bleeding].
Klingel R; Wandel E; Hafner G; Meyer zum Büschenfelde KH; Köhler H
Dtsch Med Wochenschr; 1993 Dec; 118(51-52):1878-83. PubMed ID: 8287777
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
Andrassy K
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
[TBL] [Abstract][Full Text] [Related]
8. [Appropriate dosage of unfraction heparin and low molecular weight heparin in hemodialysis patients].
Xiao Q; Sun XF; Zhang D; Ma ZF; Wu MG; Wang H; Chen XM
Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(3):187-91. PubMed ID: 20356555
[TBL] [Abstract][Full Text] [Related]
9. Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin.
Sagedal S; Hartmann A; Osnes K; Bjørnsen S; Torremocha J; Fauchald P; Kofstad J; Brosstad F
Nephrol Dial Transplant; 2006 Feb; 21(2):444-9. PubMed ID: 16234293
[TBL] [Abstract][Full Text] [Related]
10. The AN69 ST haemodialysis membrane under conditions of two different extracorporeal circuit rinse protocols a comparison of thrombogenicity parameters.
Richtrova P; Opatrny K; Vit L; Sefrna F; Perlik R
Nephrol Dial Transplant; 2007 Oct; 22(10):2978-84. PubMed ID: 17597089
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations.
Ovrum E; Tangen G; Oystese R; Ringdal MA; Istad R
J Thorac Cardiovasc Surg; 2001 Feb; 121(2):324-30. PubMed ID: 11174738
[TBL] [Abstract][Full Text] [Related]
12. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis.
Liu ZQ; Wang L
Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct; 22(10):942-3. PubMed ID: 12377628
[TBL] [Abstract][Full Text] [Related]
13. Review: anticoagulation for haemodialysis.
Suranyi M; Chow JS
Nephrology (Carlton); 2010 Jun; 15(4):386-92. PubMed ID: 20609088
[TBL] [Abstract][Full Text] [Related]
14. Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility?
Gritters M; Borgdorff P; Grooteman MP; Schoorl M; Schoorl M; Bartels PC; Tangelder GJ; Nubé MJ
Nephrol Dial Transplant; 2008 Sep; 23(9):2911-7. PubMed ID: 18364368
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during haemodialysis.
Tao M; Zheng D; Liang X; Ye M; Liu Y; Li Y; Shen H; He Q
Nephrology (Carlton); 2020 Sep; 25(9):723-729. PubMed ID: 31999031
[TBL] [Abstract][Full Text] [Related]
16. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing.
Näsström B; Stegmayr B; Gupta J; Olivecrona G; Olivecrona T
Nephrol Dial Transplant; 2005 Jun; 20(6):1172-9. PubMed ID: 15797889
[TBL] [Abstract][Full Text] [Related]
17. [Preparation and antithrombogenicity of oxidated low molecular weight heparin-antithrombin complex coated-polyvinyl chloride tubing].
Luo P; Liu W; Yang C; Zhou H; Cao R; Yang J
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2011 Feb; 28(1):90-4. PubMed ID: 21485191
[TBL] [Abstract][Full Text] [Related]
18. The safety of heparins in end-stage renal disease.
Sonawane S; Kasbekar N; Berns JS
Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of low molecular weight heparin anticoagulation during haemodialysis with a Sonoclot Analyzer.
Schött U; Nilsson LG; Broman M; Engström M
Perfusion; 2010 Jul; 25(4):191-6. PubMed ID: 20530518
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
